D2G Oncology has a proprietary platform that enables highly multiplexed and quantitative analysis of the growth of precisely-engineered tumor genotypes in GEM models of cancer (including KrasG12C/D). The scalability of our platform has allowed us to identify novel and clinically-validated gene-gene and gene-drug interactions, and its flexibility also permits target identification and validation efforts. Partner with us to help guide drug discovery, patient selection, and clinical strategies for the successful development of drug candidates.
Biodesix® is an experienced partner in the field of blood-based molecular diagnostic testing. Our comprehensive diagnostic testing capabilities help our partners decipher the complexity of cancer by interpreting genomic and proteomic information from both tumor biology and the patient’s immune response. Biodesix enables our partners throughout the discovery, development and commercialization of personalized diagnostics to support new therapies with companion diagnostic strategies.
Biodesy has developed a unique technology to detect structural changes in biomolecules, based on a phenomenon called second-harmonic generation (SHG), with applications in drug discovery and structural biology. Our sensitive, mass-independent platform can detect even weak affinity interactions, enabling a variety of approaches for challenging targets, including fragment-based discovery for KRas. In addition to our flagship product, the Delta™, we provide access to the technology through services to accomplish defined deliverables and in-depth research collaborations.
We share your passion for science. Promega is committed to excellence in developing a broad suite of technologies for oncology. Learn how NanoBRET Target Engagement technology is being used to: target histone deacetylases, bromodomains, kinases, E3 ligases, and GPCRs; perform quantitative determinations of test compound affinity; monitor ligand occupancy in live cells, in real-time; and adapted for use in broad-spectrum profiling to evaluate the live-cell selectivity for test compounds. Let’s collaborate.
AssayQuant® is a Life Science company developing innovative enzyme assays for a quantum improvement in performance and productivity to accelerate discovery and drug development. We combine chelation-enhanced fluorescence with high-throughput peptide synthesis methods to create optimized physiologically based sensors. The result is a simple yet powerful method that allows continuous, quantitative and homogenous detection of protein kinase and phosphatase activity, both up- and downstream of Ras, using recombinant enzymes or crude cell or tissue lysates.
Onconova Therapeutics, Inc. is a Phase 3 stage biopharmaceutical company focused on developing novel small molecule drug candidates to treat cancer. Advanced clinical trials with our lead compound, rigosertib, a Ras mimetic, are aimed at patients with myelodysplastic syndromes (MDS), a hematological malignancy. Rigosertib will also be studied in Kras + NSCLC in combination with a PD-1 inhibitor in patients who have failed first-line therapies. Preclinical studies are also underway in Ras+ pediatric cancers.